August 7, 2008 – MEDRAD Inc. completed today the first installation of its Intego PET Infusion System at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center.
MEDRAD has partnered with IBA Molecular which will supply UPMC with Fluorodeoxyglucose (FDG) in a multi-dose vial housed in a specially-designed Tungsten vial shield. Use of this system is said to minimize the need to manually prepare and handle individual FDG doses, significantly reducing potential radiation exposure to hospital personnel.
The Intego System automates the administration of FDG for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures. By automating and controlling FDG dosing and infusion, the Intego System is designed to precisely and safely administer FDG to patients throughout the day.
The Intego System automatically extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient; minimizing the need for manual dose preparation and associated handling, as well as protecting the technologist from the corresponding radiation exposure. With the Intego System’s dose-on-demand capability, the prescribed dose may be administered when the patient and technologist are ready, enabling technologists to easily and efficiently respond to schedule changes, patient delays, and add-on patients.
MEDRAD recently received U.S. FDA 510(k) clearance for the Intego PET Infusion System.
For more information: www.iba-molecular.com and www.medrad.com
October 28, 2026 
